BTIG initiated coverage of VYNE Therapeutics (VYNE) with a Buy rating and $8 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYNE:
Education
About Us
Working with TipRanks
Follow Us
